The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice

Seokmann Hong, Michael T. Wilson, Isao Serizawa, Lan Wu, Nagendra Singh, Olga V. Naidenko, Toru Miura, Tomoku Haba, David C. Scherer, Jie Wei, Mitchell Kronenberg, Yasuhiko Koezuka, Luc Van Kaer

Research output: Contribution to journalArticle

498 Citations (Scopus)

Abstract

Diabetes in non-obese diabetic (NOD) mice is mediated by pathogenic T-helper type 1 (Th1) cells that arise because of a deficiency in regulatory or suppressor T cells. Vα14-Jα15 natural killer T (NKT) cells recognize lipid antigens presented by the major histocompatibility complex class I-like protein CD1d (refs. 3, 4). We have previously shown that in vivo activation of Vα14 NKT cells by α-galactosylceramide (α-GalCer) and CD1d potentiates Th2-mediated adaptive immune responses. Here we show that α-GalCer prevents development of diabetes in wild-type but not CD1d-deficient NOD mice. Disease prevention correlated with the ability of αGalCer to suppress interferon-γ but not interleukin-4 production by NKT cells, to increase serum immunoglobulin E levels, and to promote the generation of islet autoantigen-specific Th2 cells. Because α-GalCer recognition by NKT cells is conserved among mice and humans, these findings indicate that α-GalCer might be useful for therapeutic intervention in human diseases characterized by Th1-mediated pathology such as Type 1 diabetes.

Original languageEnglish (US)
Pages (from-to)1052-1056
Number of pages5
JournalNature Medicine
Volume7
Issue number9
DOIs
StatePublished - Jan 1 2001
Externally publishedYes

Fingerprint

Galactosylceramides
Inbred NOD Mouse
Natural Killer T-Cells
T-cells
Medical problems
Type 1 Diabetes Mellitus
Ligands
Th2 Cells
Th1 Cells
Autoantigens
Adaptive Immunity
Major Histocompatibility Complex
Interleukin-4
Interferons
Immunoglobulin E
Pathology
T-Lymphocytes
Lipids
Antigens
Chemical activation

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. / Hong, Seokmann; Wilson, Michael T.; Serizawa, Isao; Wu, Lan; Singh, Nagendra; Naidenko, Olga V.; Miura, Toru; Haba, Tomoku; Scherer, David C.; Wei, Jie; Kronenberg, Mitchell; Koezuka, Yasuhiko; Van Kaer, Luc.

In: Nature Medicine, Vol. 7, No. 9, 01.01.2001, p. 1052-1056.

Research output: Contribution to journalArticle

Hong, S, Wilson, MT, Serizawa, I, Wu, L, Singh, N, Naidenko, OV, Miura, T, Haba, T, Scherer, DC, Wei, J, Kronenberg, M, Koezuka, Y & Van Kaer, L 2001, 'The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice', Nature Medicine, vol. 7, no. 9, pp. 1052-1056. https://doi.org/10.1038/nm0901-1052
Hong, Seokmann ; Wilson, Michael T. ; Serizawa, Isao ; Wu, Lan ; Singh, Nagendra ; Naidenko, Olga V. ; Miura, Toru ; Haba, Tomoku ; Scherer, David C. ; Wei, Jie ; Kronenberg, Mitchell ; Koezuka, Yasuhiko ; Van Kaer, Luc. / The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. In: Nature Medicine. 2001 ; Vol. 7, No. 9. pp. 1052-1056.
@article{100bd033fb0d4cc09cfc22ad184475f7,
title = "The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice",
abstract = "Diabetes in non-obese diabetic (NOD) mice is mediated by pathogenic T-helper type 1 (Th1) cells that arise because of a deficiency in regulatory or suppressor T cells. Vα14-Jα15 natural killer T (NKT) cells recognize lipid antigens presented by the major histocompatibility complex class I-like protein CD1d (refs. 3, 4). We have previously shown that in vivo activation of Vα14 NKT cells by α-galactosylceramide (α-GalCer) and CD1d potentiates Th2-mediated adaptive immune responses. Here we show that α-GalCer prevents development of diabetes in wild-type but not CD1d-deficient NOD mice. Disease prevention correlated with the ability of αGalCer to suppress interferon-γ but not interleukin-4 production by NKT cells, to increase serum immunoglobulin E levels, and to promote the generation of islet autoantigen-specific Th2 cells. Because α-GalCer recognition by NKT cells is conserved among mice and humans, these findings indicate that α-GalCer might be useful for therapeutic intervention in human diseases characterized by Th1-mediated pathology such as Type 1 diabetes.",
author = "Seokmann Hong and Wilson, {Michael T.} and Isao Serizawa and Lan Wu and Nagendra Singh and Naidenko, {Olga V.} and Toru Miura and Tomoku Haba and Scherer, {David C.} and Jie Wei and Mitchell Kronenberg and Yasuhiko Koezuka and {Van Kaer}, Luc",
year = "2001",
month = "1",
day = "1",
doi = "10.1038/nm0901-1052",
language = "English (US)",
volume = "7",
pages = "1052--1056",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - The natural killer T-cell ligand α-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice

AU - Hong, Seokmann

AU - Wilson, Michael T.

AU - Serizawa, Isao

AU - Wu, Lan

AU - Singh, Nagendra

AU - Naidenko, Olga V.

AU - Miura, Toru

AU - Haba, Tomoku

AU - Scherer, David C.

AU - Wei, Jie

AU - Kronenberg, Mitchell

AU - Koezuka, Yasuhiko

AU - Van Kaer, Luc

PY - 2001/1/1

Y1 - 2001/1/1

N2 - Diabetes in non-obese diabetic (NOD) mice is mediated by pathogenic T-helper type 1 (Th1) cells that arise because of a deficiency in regulatory or suppressor T cells. Vα14-Jα15 natural killer T (NKT) cells recognize lipid antigens presented by the major histocompatibility complex class I-like protein CD1d (refs. 3, 4). We have previously shown that in vivo activation of Vα14 NKT cells by α-galactosylceramide (α-GalCer) and CD1d potentiates Th2-mediated adaptive immune responses. Here we show that α-GalCer prevents development of diabetes in wild-type but not CD1d-deficient NOD mice. Disease prevention correlated with the ability of αGalCer to suppress interferon-γ but not interleukin-4 production by NKT cells, to increase serum immunoglobulin E levels, and to promote the generation of islet autoantigen-specific Th2 cells. Because α-GalCer recognition by NKT cells is conserved among mice and humans, these findings indicate that α-GalCer might be useful for therapeutic intervention in human diseases characterized by Th1-mediated pathology such as Type 1 diabetes.

AB - Diabetes in non-obese diabetic (NOD) mice is mediated by pathogenic T-helper type 1 (Th1) cells that arise because of a deficiency in regulatory or suppressor T cells. Vα14-Jα15 natural killer T (NKT) cells recognize lipid antigens presented by the major histocompatibility complex class I-like protein CD1d (refs. 3, 4). We have previously shown that in vivo activation of Vα14 NKT cells by α-galactosylceramide (α-GalCer) and CD1d potentiates Th2-mediated adaptive immune responses. Here we show that α-GalCer prevents development of diabetes in wild-type but not CD1d-deficient NOD mice. Disease prevention correlated with the ability of αGalCer to suppress interferon-γ but not interleukin-4 production by NKT cells, to increase serum immunoglobulin E levels, and to promote the generation of islet autoantigen-specific Th2 cells. Because α-GalCer recognition by NKT cells is conserved among mice and humans, these findings indicate that α-GalCer might be useful for therapeutic intervention in human diseases characterized by Th1-mediated pathology such as Type 1 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=0034786013&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034786013&partnerID=8YFLogxK

U2 - 10.1038/nm0901-1052

DO - 10.1038/nm0901-1052

M3 - Article

C2 - 11533710

AN - SCOPUS:0034786013

VL - 7

SP - 1052

EP - 1056

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 9

ER -